SpringWorks/SWTX

$44.11

1.63%
-
1D1W1MYTD1YMAX

About SpringWorks

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Ticker

SWTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Saqib Islam

Employees

305

Headquarters

Stamford, United States

SpringWorks Metrics

BasicAdvanced
$3.15B
Market cap
-
P/E ratio
-$5.14
EPS
0.86
Beta
-
Dividend rate
$3.15B
0.85778
$53.92
$18.00
1.12M
6.408
6.368
-47.95%
-54.9%
-53%
577.985
4.989
5.119
1.72%
-46.21%

What the Analysts think about SpringWorks

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
51.33% upside
High $80.00
Low $58.00
$44.11
Current price
$66.75
Average price target

SpringWorks Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,746.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.4M
∞%
Net income
$-94.3M
18.77%
Profit margin
-1,746.29%
-∞%

SpringWorks Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.89%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.18
-$1.25
-$1.27
-$1.45
-
Expected
-$1.24
-$1.26
-$1.33
-$1.24
-$1.19
Surprise
-4.99%
-0.95%
-4.51%
16.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for SpringWorks stock?

SpringWorks (SWTX) has a market cap of $3.15B as of April 17, 2024.

What is the P/E ratio for SpringWorks stock?

The price to earnings (P/E) ratio for SpringWorks (SWTX) stock is 0 as of April 17, 2024.

Does SpringWorks stock pay dividends?

No, SpringWorks (SWTX) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next SpringWorks dividend payment date?

SpringWorks (SWTX) stock does not pay dividends to its shareholders.

What is the beta indicator for SpringWorks?

SpringWorks (SWTX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the SpringWorks stock price target?

The target price for SpringWorks (SWTX) stock is $66.75, which is 51.33% above the current price of $44.11. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell SpringWorks stock

Buy or sell SpringWorks stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing